New Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials

ConclusionIn participants of clinical trials aged 75 and older, NOACs did not cause excess bleeding and were associated with equal or greater efficacy than conventional therapy.
Source: Journal of the American Geriatrics Society - Category: Geriatrics Authors: Tags: Clinical Investigations Source Type: research

Related Links:

This article reviews up to date data about the risk of gastric bleeding on dabigatran, the impact of PPI on the reduction of gastric bleeding, and the interaction between PPI and dabigatran leading to decreased dabigatran plasma levels. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Seminars in Thrombosis and Hemostasis - Category: Hematology Authors: Tags: Review Article Source Type: research
Conclusions The presence of comorbidities was linked to NOAC use over vitamin K antagonist, which is different from prescription factor studies in other countries and requires further study.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - Category: Cardiology Authors: Tags: POINT OF VIEW Source Type: research
AbstractHalf of patients with atrial fibrillation (AF) and elevated stroke risk do not receive anticoagulation (AC). Explanations for undertreatment may relate to provider lack of confidence with or knowledge of the CHA2DS2-VASc stroke calculator, unfamiliarity with direct oral anticoagulants (DOACs), or uncertainty about use of AC after bleeding events or other challenging patient scenarios. We surveyed cardiology and primary care providers (PCPs) within a large healthcare system to investigate prescriber knowledge, confidence, and comfort prescribing AC for AF in challenging scenarios. Of 112 providers invited, 70 (63%) ...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
CONCLUSION: The majority of deaths are not related to stroke in patients with AF after the LAAO procedure. Mortality in first 2 years following the procedure was predominantly from non-cardiovascular causes. Key words: atrial fibrillation, LAAO, left atrial appendage, stroke. PMID: 31495824 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - Category: Cardiology Authors: Tags: Kardiol Pol Source Type: research
Oral anticoagulants have been widely used in patients with atrial fibrillation (AF), mechanical valve and in the treatment of both arterial and venous thromboembolism (VTE). Warfarin is the conventional oral anticoagulant which was established its efficacy and safety profiles. Direct oral anticoagulants (DOACs) including dabigatran, rivaroxaban, and apixaban, have gained their popularity and been increasingly used since their approval in Thailand for stroke prevention in AF and VTE treatment.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
Direct oral anticoagulants (DOACs) are now a mainstay of anticoagulant therapy for the prevention and treatment of venous thromboembolism (VTE) and stroke prevention in non-valvular atrial fibrillation (a-fib). However, bleeding-related morbidity and mortality remains a feared complication. Bleeding in patients taking DOACs in clinical trials showed comparable, if not more favorable, outcomes compared to that of warfarin [1 –4]. However, the safety of DOAC use should also be evaluated in less selected cohorts in the real-world.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
AbstractOral anticoagulants (OACs) are effective in preventing stroke in older people with atrial fibrillation (AF), but they are often underused in this particularly high-risk population. The aim of the study was to identify health and functional determinants of oral anticoagulant therapy (OA) in AF at discharge from a geriatric sub-acute ward. A cross-sectional study was conducted and patients who presented with atrial fibrillation were analyzed. They were interviewed, examined, assessed with comprehensive geriatric assessment protocol, and had their hospital records analyzed. Relative risks for OA were counted and multi...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
This study was conducted to clarify CV and bleeding events in Japanese aspirin users with a history of CV diseases. This study was a prospective, nationwide, multicenter cooperative registry of Japanese patients with CV diseases at risk of thromboembolism who were taking aspirin (75–325 mg) for at least 1 year. We observed major CV and bleeding events during follow-up. Patients with history of ischemic stroke (IS), transient ischemic attack (TIA), coronary artery disease (CAD), atrial fibrillation (AF), and venous thromboembolism (VTE) were included and analyzed in this sutdy. CV events included IS, TIA, CA...
Source: Heart and Vessels - Category: Cardiology Source Type: research
AbstractThe approved dose of oral anticoagulant rivaroxaban for patients with non-valvular atrial fibrillation (NVAF) in Japan is 15  mg once daily (od) in patients whose creatinine clearance is ≥ 50 mL/min, but recent real-world studies have demonstrated that these patients often received less than the recommended dose due to bleeding concerns. The effect of under-dosing on safety and effectiveness outcomes remains uncle ar. We used 1-year follow-up data from the XAPASS, a real-world Japanese prospective, single-arm, observational study. Of the 11,308 patients, 6521 patients who completed a 1-ye...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
More News: Atrial Fibrillation | Bleeding | Clinical Trials | Databases & Libraries | Geriatrics | Pradaxa | Science | Stroke | Thrombosis